Quadrature Capital Ltd Makes New $1.19 Million Investment in TransMedics Group, Inc. $TMDX

Quadrature Capital Ltd purchased a new stake in TransMedics Group, Inc. (NASDAQ:TMDX) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 8,907 shares of the company’s stock, valued at approximately $1,193,000.

A number of other institutional investors and hedge funds also recently modified their holdings of TMDX. Opal Wealth Advisors LLC acquired a new position in shares of TransMedics Group in the 2nd quarter worth $26,000. Smartleaf Asset Management LLC lifted its holdings in shares of TransMedics Group by 44.3% during the first quarter. Smartleaf Asset Management LLC now owns 440 shares of the company’s stock valued at $30,000 after purchasing an additional 135 shares during the last quarter. Quarry LP lifted its holdings in shares of TransMedics Group by 88.5% during the first quarter. Quarry LP now owns 592 shares of the company’s stock valued at $40,000 after purchasing an additional 278 shares during the last quarter. Sound Income Strategies LLC acquired a new position in shares of TransMedics Group in the 2nd quarter valued at $48,000. Finally, Elevation Point Wealth Partners LLC purchased a new position in TransMedics Group in the 2nd quarter worth about $48,000. Institutional investors and hedge funds own 99.67% of the company’s stock.

Insider Buying and Selling at TransMedics Group

In related news, Director Edward M. Basile sold 4,142 shares of the stock in a transaction on Wednesday, October 29th. The stock was sold at an average price of $130.45, for a total transaction of $540,323.90. Following the completion of the sale, the director directly owned 2,866 shares in the company, valued at approximately $373,869.70. This trade represents a 59.10% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Anil P. Ranganath sold 3,000 shares of TransMedics Group stock in a transaction on Tuesday, November 25th. The shares were sold at an average price of $145.22, for a total value of $435,660.00. Following the sale, the insider directly owned 13,955 shares of the company’s stock, valued at approximately $2,026,545.10. The trade was a 17.69% decrease in their position. The disclosure for this sale is available in the SEC filing. 7.00% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

TMDX has been the subject of a number of analyst reports. Needham & Company LLC reaffirmed a “buy” rating on shares of TransMedics Group in a research note on Thursday, October 30th. Stifel Nicolaus initiated coverage on shares of TransMedics Group in a research report on Thursday, September 4th. They issued a “hold” rating and a $115.00 target price on the stock. Zacks Research downgraded shares of TransMedics Group from a “strong-buy” rating to a “hold” rating in a research report on Monday, October 6th. Jefferies Financial Group initiated coverage on shares of TransMedics Group in a research note on Monday, October 13th. They issued a “buy” rating and a $145.00 price objective for the company. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of TransMedics Group in a research report on Wednesday, October 8th. Seven analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $131.80.

TransMedics Group Price Performance

NASDAQ TMDX opened at $145.95 on Monday. The company has a debt-to-equity ratio of 1.43, a current ratio of 7.69 and a quick ratio of 7.13. The firm has a market capitalization of $4.99 billion, a price-to-earnings ratio of 59.09 and a beta of 2.05. The company has a 50 day simple moving average of $122.67 and a 200-day simple moving average of $122.18. TransMedics Group, Inc. has a 52-week low of $55.00 and a 52-week high of $148.59.

TransMedics Group (NASDAQ:TMDX) last released its quarterly earnings data on Wednesday, October 29th. The company reported $0.66 earnings per share for the quarter, beating the consensus estimate of $0.37 by $0.29. TransMedics Group had a net margin of 16.20% and a return on equity of 31.42%. The firm had revenue of $143.82 million for the quarter, compared to analyst estimates of $145.33 million. During the same quarter in the prior year, the business earned $0.12 EPS. The company’s revenue for the quarter was up 32.2% compared to the same quarter last year. TransMedics Group has set its FY 2025 guidance at EPS. Equities research analysts predict that TransMedics Group, Inc. will post 1 earnings per share for the current fiscal year.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.